Found 35 clinical trials
Validation of Standardized Test Protocols to Assess the Impact of Visual Pathologies in Daily Life Activities
conditions but also in virtual reality (VR). This tool can be used to measure a therapeutic benefit for new treatments (like gene therapy, retinal implants, intra vitreous injections ) for visual loss
- 2 views
- 24 Jan, 2021
- 1 location
Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial
the venous sinus may improve patients' objective symptoms (such as visual loss and papilledema) and subjective symptoms (such as headache). This study will determine whether dural venous sinus
- 0 views
- 29 Sep, 2021
- 2 locations
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (TELeMAC)
manifestations of Coats' disease. It can be complicated by macular edema due to leakage from microvascular ectasia. When associated with visual loss, macular edema can be treated with different strategies
- 0 views
- 15 Feb, 2022
- 1 location
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African
- 0 views
- 28 Jan, 2021
- 1 location
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
untreated or insufficiently treated, scleritis can progress to peripheral ulcerative keratitis, uveitis and glaucoma. Visual loss occurs in approximately 10% of patients with anterior scleritis and in up to
- 0 views
- 24 Jan, 2021
- 1 location
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely-used, effective anti-vascular endothelial growth factor treatment regimen for neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to investigate the 18-month …
- 0 views
- 04 Mar, 2021
- 1 location
Quantification of Metamorphopsia in Patients With Epiretinal Membranes
Aim of this study is to examine metamorphopsia before and 3 months after vitrectomy with membrane peeling among patients with idiopathic epiretinal membranes. Therefore, the correlation between the Alleye App and the M-chart test before and after ERM surgery and the associations of OCT biomarkers to postsurgical changes in metamorphopsia …
- 0 views
- 22 Dec, 2021
- 1 location
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) (ReCOVER)
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior …
- 51 views
- 23 Feb, 2022
- 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …
- 124 views
- 18 Feb, 2022
- 18 locations
Effect of Coffee and Tea Consumption on Adolescent Weight Control
Introduction: The influence of tea or coffee supplementation on body weight in adolescents has never been tested. The aim of the present study was to investigate the effect of tea and coffee consumption on body weight and body fat in an obese adolescent population. Methods: Randomized clinical trial, parallel group …
- 0 views
- 25 Mar, 2022